Home » Newsletters » BioWorld Science

BioWorld Science

April 29, 2011

View Archived Issues

AZD-4547 shows preclinical potential to treat solid tumors

TTAC-0001 displays antitumor efficacy in various models

Second-generation tumor metabolism inhibitor PENAO shows promise in vitro and in vivo

Antibody-drug conjugate BAY-94-9343 is active against mesothelin-expressing tumors

Novel inhibitors of human neutrophil elastase prepared

Nano Terra licenses three new products to Kadmon Pharma

Genetic markers of prostate cancer mortality identified in castration-resistant disease

AY-4 inhibits tumor growth in model of head and neck cancer

TransTech patents new compounds for Alzheimer's disease

Kuros Biosurgery regains rights to several products from Baxter

Vical reports promising phase I data on Vaxfectin-adjuvanted H1N1 pandemic flu vaccine

Merck & Co. presents new melanin-concentrating hormone MCH1 receptor antagonists

Eli Lilly and Medtronic form drug-device collaboration for Parkinson's disease

FDA approves additional indication for Lamictal XR

Novel PET tracers presented by University of Zagreb

Columbia Labs submits NDA to FDA for Prochieve to reduce risk of preterm birth

New antiprotozoal compounds reported

Dyax and Five Prime join to identify therapeutic antibodies against multiple targets

Primary endpoints met in phase II Vyvans trial in schizophrenia

Capstone Therapeutics reports final data from phase IIa AZX-100 trial

Adherex Technologies enrolls first patient in phase II eniluracil trial

OncoMed receives FDA clearance to advance anticancer candidate OMP-18R5 into phase I

FDA approves Zytiga in combination with prednisone for metastatic CRPC

Unigene completes enrollment in phase II study of oral parathyroid hormone for osteoporosis

Mirapex LA tablet approved in Japan for Parkinson's disease

Karo Bio and Alkem Laboratories enter collaboration and license agreement for eprotirome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 27, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Sumitomo’s DSP-3456 exerts antidepressant-like effects
BioWorld Science
About one-third of patients with major depressive disorder (MDD) are treatment resistant. Ketamine is very effective in treatment-resistant depression, but it is...